for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Avalo Therapeutics Inc

avtx.oq

Latest Trade

2.16USD

Change

-0.02(-0.92%)

Volume

14,947

Today's Range

2.13

 - 

2.20

52 Week Range

1.99

 - 

4.49

As of on the NASDAQ ∙ Minimum 15 minute delay

Latest Developments

Point72 Asset Management Reports 5.4% Passive Stake In Avalo Therapeutics As Of Sept. 17

Sept 21 (Reuters) - Point72 Asset Management LP::POINT72 ASSET MANAGEMENT LP REPORTS 5.4% PASSIVE STAKE IN AVALO THERAPEUTICS INC AS OF SEPTEMBER 17 - SEC FILING.Further company coverage: AVTX.O. ((Reuters.Briefs@thomsonreuters.com;)).

Avalo Therapeutics Inc Announces Pricing Of $27.5 Million Public Offering Of Common Stock

Sept 14 (Reuters) - Avalo Therapeutics Inc <AVTX.O>::AVALO THERAPEUTICS, INC. ANNOUNCES PRICING OF $27.5 MILLION PUBLIC OFFERING OF COMMON STOCK.SAYS PUBLIC OFFERING PRICED AT $2.20PER SHARE.

Avalo Therapeutics, Inc. Announces Proposed Public Offering Of Common Stock

Sept 14 (Reuters) - Avalo Therapeutics Inc <AVTX.O>::AVALO THERAPEUTICS, INC. ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK.AVALO THERAPEUTICS - INTENDS TO USE NET PROCEEDS OF OFFERING FOR WORKING CAPITAL, OTHER GENERAL CORPORATE PURPOSES.

Cerecor Reports Q2 2021 Financial Results

Aug 2 (Reuters) - Cerecor Inc <CERC.O>::CERECOR REPORTS SECOND QUARTER 2021 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATES.COMPLETED $35 MILLION DEBT FINANCING THAT EXTENDS CASH RUNWAY, SUPPORTS MULTIPLE CLINICAL CATALYSTS ANTICIPATED IN SECOND HALF OF 2021.QTRLY LOSS PER SHARE $0.18.AS OF JUNE 30, 2021, CERECOR HAD $40.4 MILLION IN CASH AND CASH EQUIVALENTS.Q2 EARNINGS PER SHARE VIEW $-0.17 -- REFINITIV IBES DATA.

Cerecor Reports Positive Initial Results for CERC-002 in Moderate to Severe Crohn's Disease Patients

July 26 (Reuters) - Cerecor Inc <CERC.O>::CERECOR ANNOUNCES POSITIVE INITIAL PHASE 1B RESULTS FOR CERC-002 IN MODERATE TO SEVERE CROHN'S DISEASE PATIENTS.CERECOR INC - CLINICALLY MEANINGFUL ENDOSCOPIC IMPROVEMENT IN 75% (3/4) OF SUBJECTS, AS DETERMINED BY COLONOSCOPY.CERECOR INC - CERC-002 WAS WELL TOLERATED WITH NO DRUG-RELATED SEVERE ADVERSE EVENTS.CERECOR INC - MEAN REDUCTION IN LIGHT LEVELS OF APPROXIMATELY 80% COMPARED TO BASELINE SIGNIFY A DRAMATIC AND RAPID REDUCTION OF LIGHT LEVELS.CERECOR INC - COHORT 2 (3.0 MG/KG DOSE) FULLY ENROLLED; COMPLETE DATA ANTICIPATED IN 2H21.CERECOR - PROMISING INITIAL RESULTS SUPPORT EXPANSION TO PATIENTS WITH MODERATE TO SEVERE ULCERATIVE COLITIS REFRACTORY TO ANTI-TNF ALPHA THERAPIES.CERECOR INC - BELIEVES THIS SECOND POSITIVE PROOF-OF-CONCEPT STUDY WITH CERC-002 FURTHER VALIDATES LIGHT MECHANISM OF ACTION IN INFLAMMATORY DISEASES.

Cerecor Enters Into $35 Mln Debt Financing Agreement With Horizon Technology Finance

June 7 (Reuters) - Cerecor Inc <CERC.O>::CERECOR ENTERS INTO $35 MILLION DEBT FINANCING AGREEMENT WITH HORIZON TECHNOLOGY FINANCE.CERECOR INC - AN INITIAL TRANCHE OF $20 MILLION DRAWN AT LOAN CLOSING.CERECOR INC - FINANCING PROVIDES FLEXIBILITY AND EXTENDS RUNWAY THROUGH MULTIPLE CLINICAL CATALYSTS EXPECTED IN 2021.CERECOR INC - FUNDS ONGOING CLINICAL DEVELOPMENT OF KEY INVESTIGATIONAL PRODUCT CANDIDATES.CERECOR INC - ISSUED HORIZON WARRANTS TO PURCHASE UP TO 403,844 OF ITS COMMON SHARES AT EXERCISE PRICE OF $2.60 PER SHARE.

Cerecor Says FDA Granted Fast Track Designation To CERC-002

May 11 (Reuters) - Cerecor Inc <CERC.O>::FDA GRANTS FAST TRACK DESIGNATION TO CERC-002 FOR TREATMENT OF HOSPITALIZED PATIENTS WITH COVID-19.

Cerecor Announces New Worldwide License Agreement With Kyowa Kirin For Anti-LIGHT Antibody CERC-002

March 29 (Reuters) - Cerecor Inc <CERC.O>::CERECOR ANNOUNCES NEW WORLDWIDE LICENSE AGREEMENT WITH KYOWA KIRIN FOR ANTI-LIGHT ANTIBODY CERC-002.CERECOR INC - KYOWA KIRIN CO. HAS AN OPTION TO RETAIN RIGHTS FOR ALL INDICATIONS IN JAPAN.CERECOR - TO GET EXCLUSIVE RIGHTS FOR DEVELOPMENT, MANUFACTURING, COMMERCIALIZATION OF ANTIBODY FOR ALL INDICATIONS WORLDWIDE.CERECOR INC - KYOWA KIRIN WILL RECEIVE AN UP-FRONT PAYMENT FROM CERECOR.CERECOR INC - KYOWA KIRIN IS ELIGIBLE TO RECEIVE ADDITIONAL PAYMENTS BASED ON ACHIEVEMENT OF REGULATORY AND COMMERCIAL MILESTONES.

Cerecor Reports 2020 Financial Results And Provides Business Updates

March 8 (Reuters) - Cerecor Inc <CERC.O>::CERECOR REPORTS 2020 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATES.

Cerecor Announces CERC-002 Significantly Reduced Respiratory Failure, Mortality in Phase 2 Clinical Trial in Patients Hospitalized with COVID-19 ARDS

March 2 (Reuters) - Cerecor Inc <CERC.O>: :CERECOR ANNOUNCES CERC-002 SIGNIFICANTLY REDUCED RESPIRATORY FAILURE & MORTALITY IN PHASE 2 CLINICAL TRIAL IN PATIENTS HOSPITALIZED WITH COVID-19 ARDS.CERECOR - FINAL ANALYSIS INCLUSIVE OF 60-DAY SAFETY UPDATE DEMONSTRATED PHASE 2 CERC-002 TRIAL MET PRIMARY EFFICACY ENDPOINT.CERECOR - EFFICACY WAS HIGHEST IN PATIENTS OVER THE AGE OF 60 IN PHASE 2 CERC-002 TRIAL.CERECOR - CERC-002 WAS WELL-TOLERATED; NO DRUG-RELATED SERIOUS ADVERSE EFFECTS WERE REPORTED IN TRIAL.CERECOR - AT BOTH 28-DAY & 60-DAY FINAL TIMEPOINTS, ABOUT 50% TREND IN MORTALITY REDUCTION (22.5% VERSUS 10.8%) WAS OBSERVED IN PHASE 2 CERC-002 TRIAL.CERECOR - CERC-002 SHOWED STATISTICALLY SIGNIFICANT EFFICACY ON TOP OF CORTICOSTEROIDS & STANDARD OF CARE TREATMENTS IN COVID-19 ARDS.CERECOR - PLANS TO MEET WITH FDA TO DISCUSS POTENTIAL PATH TO EMERGENCY USE AUTHORIZATION FOR CERC-002.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up